Urinary Markers of Nucleic Acid Oxidation and Long-Term Mortality of Newly Diagnosed Type 2 Diabetic Patients
- Kasper Broedbaek, MD1,2⇓,
- Volkert Siersma, PHD3,
- Trine Henriksen, PHD1,2,
- Allan Weimann, PHD1,2,
- Morten Petersen, MD1,2,
- Jon T. Andersen, MD1,2,
- Espen Jimenez-Solem, MD1,2,
- Elisabeth S. Stovgaard, MD1,2,
- Lars J. Hansen, PHD3,
- Jan Erik Henriksen, PHD4,
- Steen J. Bonnema, PHD4,
- Niels de Fine Olivarius, MD3 and
- Henrik E. Poulsen, DMSC1,2,5
- 1Laboratory of Clinical Pharmacology, Rigshospitalet, Copenhagen, Denmark
- 2Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
- 3Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
- 4Department of Endocrinology, Odense University Hospital, Odense, Denmark
- 5Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
- Corresponding author: Kasper Broedbaek, .
OBJECTIVE We analyzed data from a cohort of 1,381 newly diagnosed type 2 diabetes patients to test the hypothesis that urinary markers of nucleic acid oxidation are independent predictors of mortality.
RESEARCH DESIGN AND METHODS We examined the relationship between urinary excretion of markers of DNA oxidation (8-oxo-7,8-dihydro-2′-deoxyguanosine [8-oxodG]) and RNA oxidation (8-oxo-7,8-dihydroguanosine [8-oxoGuo]) and long-term mortality using Cox proportional hazards regression.
RESULTS After multivariate adjustment, the hazard ratios for all-cause and diabetes-related mortality of patients with 8-oxoGuo levels in the highest quartile compared with those in the lowest quartile were 1.44 (1.12–1.85) and 1.54 (1.13–2.10), respectively. Conversely, no significant associations between 8-oxodG and mortality were found in the adjusted analyses.
CONCLUSIONS Urinary excretion of the RNA oxidation marker 8-oxoGuo measured shortly after diagnosis of type 2 diabetes predicts long-term mortality independently of conventional risk factors. This finding suggests that 8-oxoGuo could serve as a new clinical biomarker in diabetes.
- Received August 23, 2011.
- Accepted September 20, 2011.
- © 2011 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.